Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05628597 · ClinicalTrials.gov registry record · NA

Effects of Fos Biomedical Device on Diabetes Risk Factors and Sleep Quality in Adults at Risk for Type 2 Diabetes

A NA study of Pre Diabetes, sponsored by Griffin Hospital.

Completed
Registry status
NA
Development phase
34
Enrollment target
1
Study location

NCT05628597 is a NA study of Pre Diabetes that has completed, run by Griffin Hospital. The registered enrollment target is 34 participants, below the 729-participant average among 59 other Pre Diabetes trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05628597, a NA study of Pre Diabetes, has completed, sponsored by Griffin Hospital.

COMPLETED
Registry status
NA
Development phase
34 participants
Enrollment target
1
Study location

Study Summary

Purpose Phototherapy has an array of potential benefits in human health. The effects of a non-transdermal Fos Biomedical product (which utilizes the concept of phototherapy) on diabetes risk factors and sleep quality in people at risk for type 2 diabetes are unclear. Proposed is a single-blind randomized crossover placebo-controlled trial to assess the impact of daily use of the Fos Biomedical product for a 12-week period on cardio-metabolic risk factors and self-reported sleep quality among adults at risk for type 2 diabetes. Specific Aims * To determine the effects of the use of the Fos Biomedical product daily for 12 weeks, as compared to placebo patch, on glycemic control in adults at risk for type 2 diabetes. Specifically, to show that the use of the Fos Biomedical product for 12 weeks, as compared to placebo patch, will improve glycated hemoglobin in adults at risk for type 2 diabetes. * To assess the effects of the use of the Fos Biomedical product, versus placebo patch, for a 12-week period on insulin sensitivity, serum lipids, C-reactive protein, anthropometric measures, self-reported sleep quality, and endothelial function in adults at risk for type 2 diabetes. Specifically, to show clinically meaningful improvement or neutral effects in insulin sensitivity, serum lipids, C-reactive protein, anthropometric measures, self-reported sleep quality, and endothelial function in adults at risk for type 2 diabetes. * To assess the impact of Fos Biomedical product on liver function and kidney function in adults at risk for type 2 diabetes Hypotheses * Daily use of the Fos Biomedical product for 12 weeks will improve glycated hemoglobin in adults at risk for type 2 diabetes. * Daily use of the Fos Biomedical product for 12 weeks will improve or have neutral effects on insulin sensitivity, serum lipids, C-reactive protein, anthropometric measures, self-reported sleep quality and endothelial function in adults at risk for type 2 diabetes. * The use of the Fos Biom

Conditions Studied

Interventions

  • DEVICE Fos Biomedical patch product
  • DEVICE Fos Biomedical patch product:placebo

Study Locations (1)

Connecticut

  • Yale-Griffin Prevention Research Center - Derby

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2021-11-23
Est. Completion 2022-12-31
Phase NA

Sponsor

Griffin Hospital

22 total trials

What the Registry Record Tells You About NCT05628597

The ClinicalTrials.gov registry entry for NCT05628597 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 59 other Pre Diabetes trials with a reported enrollment target (95% lower). The listed sponsor is Griffin Hospital, which has 22 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pre Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Fos Biomedical patch product is the first listed.

NCT05628597 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT05628597 about?

NCT05628597 is a clinical study titled "Effects of Fos Biomedical Device on Diabetes Risk Factors and Sleep Quality in Adults at Risk for Type 2 Diabetes". Purpose Phototherapy has an array of potential benefits in human health. The effects of a non-transdermal Fos Biomedical product (which utilizes the concept of phototherapy) on diabetes risk factors and sleep quality in people at risk for type 2 diabetes are unclear. Proposed is a single-blind rando...

What is the current status of trial NCT05628597?

This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2021-11-23. Estimated completion is 2022-12-31.

What conditions does trial NCT05628597 study?

This clinical trial studies the following conditions: Pre Diabetes.

What interventions are being tested in trial NCT05628597?

The interventions under investigation include: Fos Biomedical patch product (DEVICE), Fos Biomedical patch product:placebo (DEVICE).

Who is sponsoring clinical trial NCT05628597?

This trial is sponsored by Griffin Hospital, which has 22 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05628597 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pre Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.